Skip to Content

Betamethasone / calcipotriene topical Pregnancy and Breastfeeding Warnings

Betamethasone / calcipotriene topical is also known as: Dovobet, Enstilar, Taclonex, Taclonex Scalp

Medically reviewed by Last updated on Jan 22, 2019.

Betamethasone / calcipotriene topical Pregnancy Warnings

Animal studies have not been reported with betamethasone-calcipotriene topical. Animal studies have revealed evidence of teratogenicity with corticosteroids administered systemically at relatively low doses. Betamethasone has been shown to be teratogenic when administered subcutaneously in mice and rabbits. Calcipotriene has been shown to be fetotoxic in animals when given systemically. There are no controlled data in human pregnancy.

FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

FDA pregnancy category: C

Potential benefit should outweigh the potential risk.

See references

Betamethasone / calcipotriene topical Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

The effects in the nursing infant are unknown.

It is unknown if there is sufficient systemic absorption with topically administered betamethasone or calcipotriene to have detectable quantities in human milk.

Betamethasone-calcipotriene topical suspension should not be used on the breast when nursing.

See references

References for pregnancy information

  1. "Product Information. Taclonex (betamethasone-calcipotriene topical)." Warner Chilcott Laboratories, Rockaway, NJ.

References for breastfeeding information

  1. "Product Information. Taclonex (betamethasone-calcipotriene topical)." Warner Chilcott Laboratories, Rockaway, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.